Inclusion/exclusion criteria is consistent with WATCHMAN clinical study inclusion/exclusion criteria. Patients must be eligible for short-term NOAC vs warfarin in previous clinical studies. Primary Safety Endpoints1 All-cause death, ischemic stroke, systemic embolism, or device- or procedure-related adver...
The trial met two of three primary end points. On safety, Watchman met the seven-day safety end point, with only six of 269 patients suffering a major complication (no deaths). Noninferiority criteria were also established in a comparison of stroke or embolism after seven days. At 18 ...